2020 National Health Care Directory Published! Negotiating drug prices reduced by an average of 50.64% domestic PD-1

Sina Pharma from the 2020 medical insurance drug catalog press conference was informed that the medical insurance drug catalog adjustment pre-preparation, according to the reporting rules, a total of 704 eligible out-of-catalog drugs passed the declaration process, the final 23 kinds of (non-exclusive) drugs were directly transferred to the catalog, 138 kinds of (exclusive) drugs were included in the scope of negotiations.
the negotiations, a total of 162 exclusive medicines were negotiated, including 138 out-of-catalog medicines and 24 out-of-catalog medicines.
, a total of 119 successful negotiations, of which 96 were successful outside the catalogue and 23 were successful in the catalogue.
of the negotiations was 73.46 per cent, with the average price reduction for successfully negotiated drugs at 50.64 per cent.
through this catalog adjustment, a total of 119 drugs were added to the catalog, and 29 original drugs were transferred out of the catalog.
total number of medicines in the Revised National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance (2020) is 2,800, of which 1,426 are Western medicines and 1,374 are Chinese medicines.
chinese medicine tablets in the catalogue were not adjusted and remained at 892.
new catalog is expected to be officially implemented on March 1 next year.
health care negotiations normal, it is said that "all must talk" this health care negotiations is one of the biggest features, according to Sina Pharmaceuticals on-site understanding, the largest number of drugs in this negotiation, the most extensive areas of treatment.
the 96 exclusive drugs eventually negotiated, plus 23 non-exclusive drugs transferred directly, involved 31 clinical groups, accounting for 86% of all clinical groups, with a broader range of patient benefits.
In addition, the first attempt to reduce the price of drugs in the catalog negotiations, evaluation experts according to the procedure to select the price or cost is high, the fund occupies more than 14 exclusive drugs to negotiate price reduction, these drugs each drug sales amount of more than 1 billion yuan.
after negotiations, all 14 drugs were successfully negotiated and kept in the catalogue, with an average price reduction of 43.46 per cent, setting a clear direction that the drugs in the original catalogue also need to continuously improve their economy.
In order to support the prevention and control of the new crown epidemic, the National Health Insurance Administration transferred libawelin injections, Abidor particles and other drugs into the catalogue, the latest version of the national new crown pneumonia diagnosis and treatment program listed drugs are all included in the national health insurance directory.
it is also worth mentioning that in order to better meet the demand for newly marketed drugs, the National Health Insurance Administration will be listed before August 17 this year in the scope of adjustment, the final 16 drugs were included in the list.
Health care negotiations are a major feature of the adjustment of the national health insurance drug catalog, the first batch of health care negotiations can be recalled in November 2015, the negotiating team and hepatitis B, non-small cell lung cancer patent drug-related enterprises in a number of rounds of negotiations, the first batch of national drug price negotiations in 2016 announced that Ektini and gifeitinib decline of more than 50%.
in 2017, the Ministry of Human and Social Affairs published a list of 44 drugs to be negotiated, and after negotiations with relevant companies, the final list of 36 drugs negotiated in July was successful, with a success rate of 81.8 percent, compared with the average retail price in 2016, the average drop in negotiated drugs reached 44 percent, the highest of 70 percent.
June 2018, the National Health Insurance Administration led the launch of a special negotiation on access to out-of-catalog cancer drugs.
after negotiations with businesses, 17 cancer drugs were included in the health-care access negotiations, and the average standard of payment for negotiated drugs fell by 56.7 percent compared to the average retail price.
2019, the fourth round of health-care negotiations, led by the National Health Care Administration, will take place in November.
150 varieties in the negotiations, 70 of the 119 new drugs were successful, an average drop of 60.7 per cent.
27 of the 31 renewals were successful, an average decrease of 26.4 per cent.
health care negotiations have gone through five times by 2020, and the negotiating mechanism is improving.
april this year, the industry also flowed out of the national health insurance drug catalog to adjust the direction of work, the new adjustment into the catalog of drugs will certainly negotiate, or participate in the national collection, that is, "all into the must talk (picking)."
of health insurance is dynamically adjusted annually and declared by the enterprise, including new products approved in the first two years of the catalog (generic name, dosage form and adaptive disorders).
Singer drug "PD-1" Heng Rui, Baiji, Junshi successfully entered December 16, Beijing minus 6 degrees, in addition to negotiating enterprises, the National People's Congress Convention Center outside the gate gathered a large number of media and securities personnel, many people are to ask about the PD-1 negotiations.
The day the negotiations ended, the industry frequently out of the participation of the 7 PD-(L)1 single resistance, Hengrui, Baiji Shenzhou, Junshi are successful negotiations, Mercado, Shishi Shiguibao, AstraZeneta, Roche all over.
, Hengrui Pharmaceutical PD-1 annual cost was passed down to about 50,000, Junshi, Baiji Shenzhou two enterprises, the price is 30,000 and 37,000, respectively.
, the domestic 3 PD-1 products have entered the health insurance catalog, imported PD-(L)1 does not appear in the health insurance catalog.
of the decline has not yet been announced.
the domestic market PD-(L)1 single anti-minimum annual treatment costs (weight 60g calculation) - PD-1 products, BMS's Navuliyu single anti-injection (commonly known as: O drug) is 22. 130,000, Mercadon's Pabli Pearl single resistance (commonly known as: K medicine) is 2867 million, Junshi's Ripley single resistance (commodity name: Toyi) is 10.08 million, Hengrui Medicine's card Reilly Pearl Single Resistance (Product Name: Erica) is 1188 million, Andrei Pearl Single Resistance (Product Name: Bazean) is 10.69 million; PD-L1 Products, AstraZeneca's The degree of valiyu monoanti (commodity name: Infeifan, commonly known as I medicine) is 2899 million, Roche's Atiliju single resistance (commodity name: Tai Sanqi, commonly known as T medicine) is 393,600.
Before the health-care catalog is published, on Christmas Eve, December 24th, the O-Drug Assistance Program will be updated again, and the program will be adjusted from the original "First 3-3, Follow-up 3-4 Cycle" to "3-3", Follow-up 3-plus. X, for example, 60 kg patients complete a year of treatment (every two weeks) out-of-the-money costs of about 480,000 yuan, and in the new scheme, the annual out-of-the-money patient costs 110,000 yuan, about a four-month listing price.
-adjusted patient assistance programme will be effective from 1 January 2021.
O drug to take the lead in adjusting the drug giveaway program, the industry predicts that K drug follow-up may also adjust the drug giveaway program.
PD-1 products are now cutting prices into the health insurance catalog, which will also have a certain impact on future users.
, as of the third quarter of 2020, there were 314 ongoing PD-1/PD-L1 clinical trials, of which 209 were bid by domestic pharmaceutical companies, and the clinical distribution of Phases I, II and III was relatively balanced, according to the Securities Research Report.
This year, Jia and Bio, Yuheng Pharmaceuticals, Zhengda Tianqing PD-1 have all submitted to the State Drug Administration for listing applications, cornerstone pharmaceutical PD-L1 single-anti-listing applications were also accepted by the State Drug Administration in November, Synth Pharmaceuticals / Corninger's first subdermal injection of PD-L1 single anti-KN035 listing applications were also recently accepted by the State Drug Administration ... Li Jin, a member of the science and technology innovation advisory committee and chairman of the Asian Cancer Alliance, also said that with more and more PD-1 products on the market, future investment in PD-1 single-resistance enterprises may encounter Waterloo.
price of SMA drug "no chance" health insurance catalog in addition to PD-1 products, this year's much-watched Nosinasi sodium injection failed to enter the health insurance catalog.
august of this year, Yan Jian's treatment of spinal muscular dystrophy ("SMA") drug - Nosinasisheng sodium injection was sold in China for 697,000 yuan each.
in Australia, however, a maximum of A$41 (about RMB205) is charged, while holding a discount card costs A$6.60 (about RMB33), which has attracted widespread attention for a while.
price disparity is due to foreign medical insurance reimbursement.
but the medicare fund plate is so big that expensive drugs squeeze the space for other drugs to enter.
previously, the industry for high PD-1 drugs should not be included in the health insurance list there has been a dispute, rare disease drug treatment costs are higher, whether to enter also depends on whether the health care fund can afford.
note that in 2019, the National Health Insurance Administration mentioned priorities for cancer and rare diseases in its new health-care directory adjustment plan.
Last year's Medicare adjustment added an oral solution for zocarnitin, which treats primary carnitine deficiency in children, and included more than a 10 rare-disease drugs, including Teflon tablets for multiple sclerosis, Megsta capsules for type C Nemanpike, and spires, porsentam tablets, maxitan tablets, and liossi tablets for the treatment of pulmonary hypertension.
Not long ago, the National Health Insurance Administration, in response to a proposal by representatives of the National People's Congress on the inclusion of medicines for rare diseases in health insurance, noted that, in general, eligible rare disease drugs have been basically included in the scope of basic medical insurance payments, and provided poor patients with rare diseases with medical assistance to solve the problem.
But from the basic medical insurance fund affordability, in 2019 urban and rural residents health insurance per capita financing of only about 800 yuan, and SMA and other rare diseases drug costs reached millions per person per year, far more than the basic health insurance capacity.
the direction of the adjustment of the national health insurance directory is mainly "guaranteed basic", some of the particularly expensive special rare disease drugs, because far beyond the fund and patient affordability, temporarily unable to be included in the scope of basic health insurance payments.
addition, Haussen Pharmaceuticals' three-generation EGFR-TKI innovative drug Amedini (trade name: Amera), Noel and Nord's Degumen winter double insulin injections, Lilly's GLP-1 permeable agitants Dora sugar peptide, Baiji Shenzhou BTK inhibitor Zebtini (commodity name: Bai Yueze), Sansheng Guojian's injection of Inito monoanti (commodity name: Septin) and so on also successfully entered the health insurance catalog.
: 2020 National Health Insurance Drug Catalog 119 negotiated successful drugs Source: CCTV News